Literature DB >> 34378838

Empagliflozin ameliorated neutropenia in a girl with glycogen storage disease Ib.

Masamitsu Mikami1, Atsushi Arai1, Hiroshi Mizumoto1.   

Abstract

Entities:  

Keywords:  1,5-anhydroglucitol; glycogen storage disease type Ib; neutropenia; sodium-glucose co-transporter 2 inhibitor

Mesh：

Substances：

Year:  2021        PMID： 34378838     DOI： 10.1111/ped.14629

Source DB:  PubMed          Journal:  Pediatr Int        ISSN： 1328-8067            Impact factor:   1.524


× No keyword cloud information.
  5 in total

1.  The overall benefits of empagliflozin treatment in adult siblings with glycogen storage disease type Ib: one year experience.

Authors:  Joanna Bidiuk; Zbigniew A Gaciong; Piotr Sobieraj
Journal:  Arch Med Sci       Date:  2022-06-23       Impact factor: 3.707

2.  Understanding the role of SGLT2 inhibitors in glycogen storage disease type Ib: the experience of one UK centre.

Authors:  Rebecca K Halligan; R Neil Dalton; Charles Turner; Katherine A Lewis; Helen R Mundy
Journal:  Orphanet J Rare Dis       Date:  2022-05-12       Impact factor: 4.303

3.  Untargeted metabolomic profiling in a patient with glycogen storage disease Ib receiving empagliflozin treatment.

Authors:  Eran Tallis; Cecile L Karsenty; Amanda B Grimes; Lina B Karam; Sarah H Elsea; Vernon Reed Sutton; Brandy L Rawls-Castillo; Ning Liu; Claudia Soler-Alfonso
Journal:  JIMD Rep       Date:  2022-05-22

4.  Repurposing of Empagliflozin as a Possible Treatment for Neutropenia and Inflammatory Bowel Disease in Glycogen Storage Disease Type Ib: A Case Report.

Authors:  Konstantinos Makrilakis; Aikaterini Barmpagianni; Maria Veiga-da-Cunha
Journal:  Cureus       Date:  2022-07-25

5.  Successful use of empagliflozin to treat neutropenia in two G6PC3-deficient children: Impact of a mutation in SGLT5.

Authors:  Cécile Boulanger; Xavier Stephenne; Jennifer Diederich; Pierre Mounkoro; Nathalie Chevalier; Alina Ferster; Emile Van Schaftingen; Maria Veiga-da-Cunha
Journal:  J Inherit Metab Dis       Date:  2022-05-24       Impact factor: 4.750
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.